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Objective: Determining the sequence in which Huntington’s disease biomarkers
become abnormal can provide important insights into the disease progression
and a quantitative tool for patient stratification. Here, we construct and present
a uniquely fine-grained model of temporal progression of Huntington’s disease
from premanifest through to manifest stages. Methods: We employ a proba-
bilistic event-based model to determine the sequence of appearance of atrophy
in brain volumes, learned from structural MRI in the Track-HD study, as well
as to estimate the uncertainty in the ordering. We use longitudinal and pheno-
typic data to demonstrate the utility of the patient staging system that the
resulting model provides. Results: The model recovers the following order of
detectable changes in brain region volumes: putamen, caudate, pallidum, insula
white matter, nonventricular cerebrospinal fluid, amygdala, optic chiasm, third
ventricle, posterior insula, and basal forebrain. This ordering is mostly pre-
served even under cross-validation of the uncertainty in the event sequence.
Longitudinal analysis performed using 6 years of follow-up data from baseline
confirms efficacy of the model, as subjects consistently move to later stages with
time, and significant correlations are observed between the estimated stages and
nonimaging phenotypic markers. Interpretation: We used a data-driven
method to provide new insight into Huntington’s disease progression as well as
new power to stage and predict conversion. Our results highlight the potential
of disease progression models, such as the event-based model, to provide new
insight into Huntington’s disease progression and to support fine-grained
patient stratification for future precision medicine in Huntington’s disease.
Introduction
Huntington’s disease (HD) is a monogenic, autosomal-
dominant neurological disorder characterized by motor,
cognitive, and behavioral symptoms that have a devastat-
ing effect on the life of the person affected.1 Symptoms
typically begin in early adult life and the disease is usually
fatal, with a median survival rate of 18 years after motor
onset.2 Despite the disease being identifiable by a single
genetic marker – an expanded cytosine-adenine-guanine
(CAG) repeat in the huntingtin gene3 – an effective dis-
ease-modifying treatment has yet to be found. This is
complicated by the difficulty in assigning gene-positive
subjects to suitable groups when conducting drug trials;
within any group there may be a range of physiological and
biophysical factors that cause a very different response to
treatment. Furthermore, HD displays an extended preman-
ifest period4,5 during which therapeutic intervention is
likely to be most effective. Identifying a suitable biomarker
that captures disease stage may potentially aid trial
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efficiency when included in a stratified statistical analysis.
While there are a range of available biomarkers from differ-
ent sources – such as functional, imaging, and genetic data
– that give some information on disease stage, none is
accurate enough alone to be useful for stratification. The
challenge therefore is to provide methods that can integrate
information from multiple biomarkers for reliable stratifi-
cation of homogeneous subgroups.
The emerging field of disease progression modeling, in
which data-driven statistical models are designed to both
describe long-term progression of the disease in terms of
a set of biomarkers and to categories the stages along that
progression of individual patients, provides a potential
solution to this challenge; a brief overview is given here,
for a more comprehensive review see.6 Hypothetical mod-
els such as those originally proposed by7 describe progres-
sion in terms of key biomarker trajectories, typically
defined as the monotonic transition from a normal to
abnormal state in an order characteristic of the disease,
where the order is hypothesized on aggregated evidence
from the literature. As such, models of this type represent
a qualitative, high-level view of the disease that do not
make direct use of subject data, thus limiting their staging
and prediction capabilities in practice.
The event-based model (EBM;8) is a probabilistic
method that infers the order in which biomarkers become
abnormal directly from cross-sectional subject data. Its key
strengths are (1) it requires no a priori staging, (2) it
requires no a priori cut points (i.e., imposed thresholds) to
define normal from abnormal, and (3) its simplicity: it can
be completely specified using only modestly sized cross-sec-
tional data (although it can also exploit longitudinal data).
Strengths (1) and (2), in particular, set the EBM apart from
more traditional region-based analyses in HD, for exam-
ple,9 which need to assign a stage to each subject a priori,
typically using ranges (cut-points) of an independent mar-
ker such as a cognitive test score, to elicit any temporal
information on the order in which volumes become detec-
tably abnormal. That limits model resolution and integrity,
as the a priori staging is imperfect. The EBM provides a
simple and robust tool for investigating disease patterns
and estimating patient stages in a fully data-driven manner.
In familial and sporadic Alzheimer’s disease,8,10 as well as
frontotemporal dementia,11 EBMs have provided staging
systems with predictive power at least as good as pattern
matching techniques, for example.12,13 In contrast to pat-
tern matching, however, the EBMs provide uniquely fine-
grained temporal patterns of atrophy, enhancing disease
understanding, and a well-defined staging system for strati-
fication. Furthermore, we highlight that the EBM advances
on more traditional region-based analyses,9 as it provides
temporal information on the order in which volumes
become detectably abnormal.
Here, we construct an EBM from the extensive and
high-quality TRACK-HD dataset (Table 1).5,14 This pro-
vides a uniquely fine-grained data-driven sequence of the
regional appearance of brain volume abnormalities in HD
and an image-based staging system. Although the original
EBM methods paper8 shows a HD model, it is for
demonstration purposes only, using a small single-centre
study, and the work makes no evaluation of the potential
for staging and prediction. The much larger dataset we
use here allows us to specify an EBM with a well-defined
ordering of events and demonstrate that it is robust
under cross-validation. Interestingly, our approach reveals
that the spread of atrophy in early-stage HD is not lim-
ited to the basal ganglia and white matter (compared to
prodromal observations, e.g., 15), but that changes in
these volumes occur first. We show the novel staging sys-
tem, the resulting EBM provides, gives strong prediction
of conversion using only imaging data. We also show
that the staging system can separate subjects within the
premanifest cohort according to predicted onset, which is
independently prescribed by a disease burden score. We
confirm the longitudinal efficacy of the model by show-
ing that patients consistently move to later stages with
time, using additional data from the TrackOn-HD
study16 to provide data 6 years from baseline. We further
validate and contextualize the EBM by showing signifi-
cant correlations between its staging predictions and
commonly used phenotypic markers, specifically: total
motor score, symbol digit modalities test, and Stroop
word reading test. As such, our model provides new
insight into the spread of pathology over the brain in
HD and new utility in patient stratification for future
precision medicine.
Table 1. Baseline demographic data for the TRACK-HD cohort.
Demographics Healthy controls Premanifest Manifest
N 119 120 118
Gender M/F 53/66 54/66 54/64
Age (years,
mean  SD)
46.3  10.2 40.8  8.8 48.5  9.9
Education (ISCED
rating, mean  SD)
4.0  1.3 3.94  1.2 3.65  1.3
CAG (repeats,
mean  SD)




1392  136 1408  151 1362  130
The TRACK-ON cohort used in this study is a subset of 91 of the pre-
manifest subjects at baseline. No significant differences in demo-
graphic data were found between the TRACK-ON subset and TRACK-
HD, except the gender ratio which is approximately 0.7 in the former
and 0.8 in the latter.
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Materials and Methods
Subjects
The TRACK-HD dataset was used in all following analy-
ses.5,14 This study uses a total of 357 subjects with clinical
diagnoses at baseline and quality-controlled imaging data –
119 healthy control (HC), 120 premanifest (pre-HD), and
118 manifest (HD) – from four different sites: Leiden (NL),
London (UK), Paris (FR), and Vancouver (CA) (Table 1).
For detailed demographic information see Table 1. Longi-
tudinal data for both the pre-HD and HD cohorts are
available for three follow-up years in the TRACK-HD
study. Additional data 6 years from baseline are supplied
by the TrackOn-HD study, which contains 69 of the HC
and 91 of the pre-HD subjects present at baseline in
TRACK-HD. The TrackOn-HD study followed the pre-
HD and control cohorts with the aim of understanding
the compensatory mechanisms that allow maintenance of
function in the presence of structural loss in the brain.
The longitudinal data are reserved for validation purposes
as the EBM requires only cross-sectional data. Both imag-
ing and phenotypic data are available for most subjects;
here, we focus on the former to construct the EBM and
use the latter for validation and to relate the EBM to clini-
cal measures.
Magnetic resonance imaging
Postprocessing of multisite 3T T1-weighted MRI was per-
formed to acquire cross-sectional regional measurements
of brain volumes. The Geodesic Information Flows (GIF)
software framework17 was used to segment and parcellate
cortical and subcortical volumes. The GIF framework
provides a more robust segmentation than other state-of-
the-art methods such as Freesurfer (http://surfer.nmr.
mgh.harvard.edu/), which has been shown to produce
noisy segmentations in some regions, for example, the
putamen.18,19
Biomarker selection
Herein, we use the term biomarker to refer to image-
based regional brain volumes that differentiate between
healthy controls (HC) and HD subjects. To control for
covariates, all cortical and subcortical volumes were cor-
rected for age, research site, and total intracranial volume
(TIV) using linear regression. To select covariate-cor-
rected volumes in a data-driven manner, a group-wise
analysis was performed between the healthy control (HC)
and HD cohorts. This approach was partly motivated by
aiming to make no a priori decision on the relevance of a
given volume, and to provide the EBM with well-defined
normal and abnormal distributions. Significant and
strongly separated volumes were defined as having
P-value P < 0.001 (corrected for multiple comparisons)
and effect size |t| > 8.0, under a two-tailed t-test. This
identified the following brain volumes (here, where rele-
vant, ‘l’ corresponds to the left volume and ‘r’ corre-
sponds to the right volume): putamen (l-r), caudate (l-r),
amygdala (l-r), pallidum (l-r), CSF, insula white matter
(l-r), third ventricle, optic chiasm, posterior insula (l-r),
and basal forebrain (l-r). Bilateral volumes were only
selected if both left and right volumes passed the require-
ments. This excluded the occipital pole and occipital
gyrus, in which the right but not the left volumes passed
the effect size requirement. We note that while it is not
safe to assume that HD affects the brain symmetrically
(see, e.g., 20), these volumes also failed the effect size cri-
terion after their bilateral volumes were combined. Fur-
thermore, the exclusion of any particular volume does
not bias the overall biomarker ordering recovered by the
EBM; the relative positions of any of the other volumes
remain unchanged, and hence it just subtracts knowledge
of the position of that particular volume in the sequence.
On the other hand, including insensitive biomarkers (i.e.,
those that do no separate patients and controls) in the
model can cause bias and counterintuitive effects. Thus,
here we take the conservative approach of excluding any
volumes over which the whole volume (left + right) does
not sufficiently discriminate between HC and HD
subjects.
We note that each of these biomarkers shows a mea-
surable difference in brain volume between HC and HD
subject. This does not imply that the change is biologi-
cally plausible, for example, it is unlikely that the optic
chiasm is directly atrophied by the disease itself. We sim-
ply assert that as the disease progresses there is a measur-
able change in each volume, and that this change is due
to disease progression and not any of the aforementioned
covariates.
The event-based model
The EBM method8,10 models a disease process as a
sequence of events at which individual biomarkers
become abnormal, based on the assumptions of mono-
tonic and homogeneous disease progression, that is,
patients experience no remission and all follow the same
pattern. It is probabilistic by design, learning normal and
abnormal distributions of each biomarker from the data,
and requires no a priori staging or cut points. It learns
the sequence of events from either or both cross-sectional
and longitudinal datasets and, importantly for clinical tri-
als, enables the assignment of a stage to a subject using
data from a single time point.
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In brief, the EBM fits a mixture model to control and
patient data for each biomarker to obtain models for the
distribution of normal and abnormal values for each bio-





of observing the value, xij, of biomarker i for
subject j, given that biomarker i has or has not become
abnormal, respectively. These likelihoods combine to cal-
culate the likelihood of the full dataset
X ¼ xij : i ¼ 1; . . .;Z; j ¼ 1; . . .N for a given sequence, S:
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Here, P kð Þis the prior likelihood of being at stage k,
which is assumed uniform to impose as little constraint
as possible, i runs over the number of events, Z, and j the
number of subjects, N. The estimation process then seeks
the characteristic sequence, S, defined as the sequence that
maximizes Equation 1. We use Markov Chain Monte
Carlo (MCMC) sampling to sample from the posterior
distribution on S and identify S, which is given by the
sample with the highest likelihood. The set of samples
further quantifies the uncertainty in the ordering; follow-
ing,8,10 we use the set of MCMC samples to construct a
positional variance diagram, which visualizes the uncer-
tainty.
Models of event distributions





obtained by fitting mixture models to the observed dis-
tributions of control and patient regional volumes. We
first fit a Gaussian distribution to the set of volumes
from the HCs, which provides the model for each
P xijj:Ei
 
. We then fit a mixture of two Gaussian distri-
butions to the set of volumes from the patients with
one component fixed to the HC model’s parameters.
The parameters of the second, fitted, component provide
the model for P xijjEi
 
. As10 notes, estimating the two
distributions is harder in sporadic diseases where the
control and patient groups are not uniquely defined.
However, our simple approach is justified here as the
control population is exactly determined by genetic test-
ing; as such, there is approaching zero probability of a
control subject developing HD, and the distribution can
be treated separately.
Patient staging
Given a characteristic event sequence, S, the EBM pro-
vides an intrinsic method for staging by evaluating, for
each subject j with data Xj, the stage k that maximizes the
likelihood10:
P XjjS; k








As in Equation 1, P kð Þ is the prior likelihood of being
at stage k, which is assumed uniform (no a priori prefer-
ence for any particular stage). The stage k that maximizes
Equation 2 defines the EBM stage of subject j. Each stage
is a highly idealized combination of normal and abnormal
biomarker values, but gives a crude picture of where the
patient lies along the characteristic sequence.
Cross-validation of event sequence
As described previously, MCMC sampling gives some
insight into the uncertainty in the event ordering esti-
mated by the EBM. However, this process tends to under-
estimate the uncertainty10; cross-validation provides a
more liberal measure of the uncertainty. Here, this is per-
formed by refitting the mixture models and re-estimating
the event sequence for 100 bootstrap samples of the data.
We construct the final positional variance diagram by
averaging over the positional variance diagrams from each
iteration.
Longitudinal consistency
We assessed the predictive capabilities of the EBM under
the hypothesis that the stage increases with time, in line
with our understanding of HD as a progressive disease.
This was tested by estimating pre-HD and HD subjects’
stages at each follow-up and comparing to baseline. The
TRACK-HD dataset is comprised of baseline measure-
ments and three follow ups: 12, 24, and 36 months from
baseline. A further year of follow-up data for the pre-HD
cohort were provided by the TrackOn-HD dataset,
extending the follow ups to 72 months. The follow-up
data were processed using the same method as the base-
line data to produce the same set of biomarkers at each
time point.
Correlation with phenotypic markers
The TRACK-HD dataset includes a number of cognitive,
functional, and motor measures for each subject at base-
line and follow-up. Here, we use the Total Motor Score
(TMS),21 Symbol Digit Modalities Test (SDMT),22 Stroop
test, and scaled CAG-age-product (CAP)23 as widely used
markers of disease-driven motor, cognitive, and genetic
onset, respectively. These markers are used to validate the
staging under the hypothesis that a subject with a high
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EBM stage will have poor motor and cognitive scores.
Furthermore, given that TMS, SDMT, Stroop, and CAP
are regularly used in clinical diagnosis, correlating these
markers with EBM stage provides both an implicit time
scale for the event sequence and insight into which events
have occurred by the time of motor onset.
Results
Region-based volumetric analysis
To aid in understanding the EBM, Figure S1 shows his-
tograms of the HC and HD volume biomarker distribu-
tions and the corresponding mixture model fits. The fits





, respectively. Note that
the volumes are covariate corrected, and hence show HC
distributions with mean zero
As a complementary and more familiar analysis, we
also provide measurements of regional volumetric changes
and estimated thresholds of abnormality for each brain
volume biomarker (see Table S1). This aids in the inter-
pretation of abnormality for each biomarker, and facili-
tates comparison with more traditional region-based
studies. Table S1 shows the percentage change in the
mean between HC and HD distributions, after correcting
for covariates (percentage change = HD residual mean/
HC mean). To facilitate comparison with other analyses
that estimate explicit thresholds for abnormality, Table S1
also shows the percentage change in each volume with
respect to the HC mean at arbitrary thresholds, which we
define here as the point at which the volume is equally
likely to be normal or abnormal. We highlight that these
thresholds are not used by the EBM; they are provided
here just to illustrate the separation of the distributions.
The volumetric changes and estimated thresholds demon-
strate good agreement with the literature, where avail-
able.9,24,25
Event sequence
Event orders are presented in the form of a positional
variance diagram, which shows the maximum likelihood
sequence and its uncertainty. As described earlier, only
HC and manifest HD subjects were used to construct the
biomarker distribution models, but all subjects were used
to produce the final event sequences. To obtain robust fits
of the distribution models, we removed all data points
more than 5 standard deviations from the within-group
mean; in practice, this excludes a single HC subject where
the segmentation overestimated the size of several vol-
umes. Cross-sectional data from a single time point were
used, so the resulting EBM does not consider biomarkers
that require follow-up scans (e.g., atrophy rates). This
ensures that data from a single time point can be used to
stage subjects.
The brain volume biomarker positional variance dia-
gram is shown in (Fig. 1A). Specifically, the order of
changes in volume is as follows: putamen, caudate, pal-
lidum, insula white matter, nonventricular CSF, amyg-
dala, optic chiasm, third ventricle, followed by the
posterior insula, and finally the basal forebrain. The cor-
responding positional variance estimated by bootstrapping
is shown in (Fig. 1B). To aid in visualization, (Fig. 1C)
shows a graphical representation of the event sequence.
Cross-validation
Figure 1B shows the positional variance of the maximum
likelihood event sequence recalculated by bootstrapping
the data (i.e., random sampling with replacement) and
refitting the mixture models and sequence. This provides
an estimation of the effect of out-of-sample variability
and hence an overestimation of the uncertainty. The
ordering is generally well preserved, with the components
of the basal ganglia occurring first, the white matter and
CSF retaining a mid-stage position, and the posterior
insula and basal forebrain occurring last.
Staging
Subjects were assigned a stage along the maximum likeli-
hood sequence defined in (Fig. 1A) according to (Eq. 2).
The fraction of subjects at each event stage for each
cohort is shown in (Fig. 2). The HC cohort is clustered at
the early stages, with the majority at stage 0 (no event
occurred), whereas the HD cohort is clustered at the late
stages, with the majority at the final stage (all events
occurred). This demonstrates that the EBM can provide
separation between healthy and manifest subjects. The
pre-HD cohort is distributed throughout the sequence
with peaks at the first and final events, indicating that
premanifest subjects can be grouped as more “HC-like”
or more “HD-like”. We further substantiate this by divid-
ing the pre-HD cohort into two subgroups, pre-HD A
and pre-HD B, which are defined by the TRACK-HD
study according to the predicted time to onset.5 The pre-
dicted time to onset is based on an age- and CAG-depen-
dent empirical relation,26 with pre-HD A subjects having
predicted onset greater than 10.8 years and pre-HD B
subjects less than 10.8 years. Accordingly, the EBM
assigns most (77%) pre-HD A subjects to the lower half
of the stages and most (67%) pre-HD B subjects to the
upper half of the stages.
Outliers appear in both the HC and HD groups, specifi-
cally one HC subject at stage 18 and the HD subjects at
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stages 0, 1, and 2. Closer inspection of these subjects sug-
gests their MRIs and regional volumes generally agree bet-
ter with those of opposite diagnosis, rather than, for
example, a single anomalous regional volume or image
processing error. The HC at stage 18 showed higher likeli-
hoods of being abnormal than normal with most of their





. We note that the HC at stage 18 is 64.9 years
old, almost 2 standard deviations greater than the mean
HC age; this may explain the anomaly even after correcting
for age (which just represents a best fit across all subjects).
The HD outliers are assigned a stage less than four because
their putamen, caudate, and pallidum all have volumes in





confirms no significant parcellation errors, suggesting that
the positions of these subjects arise simply from the broad
heterogeneity of brain structure and disease manifestation.
Longitudinal consistency
The longitudinal consistency of the EBM staging system was
first tested using follow-up data from three consecutive
years. (Fig. 3A–C) show the EBM stages at baseline versus
the EBM stages at each follow-up (year 1, 2, and 3) along
with the bootstrapped positional variance in the event
sequence from (Fig. 1B). It confirms that the subject stages
generally increase, stay constant with time, or lie within
model uncertainty, as expected. At the final year only three
subjects regress more than a single stage from baseline; all of
these were at the final stage at baseline. Closer inspection
reveals that the small fluctuations in stage arise from the
fluctuation of estimated basal forebrain volumes at either
baseline or follow-up. These volumes are prone to causing
model error as the HC distribution’s standard deviation is
larger than that of the HD distribution (approximately a fac-
tor of 1.3). The additional follow-up data provided by the
TrackOn-HD study were included to provide a further
3 years of validation for most (91/120) of the premanifest
cohort. A generally increasing trend of stage with time was
observed, with 92% of patients staged greater than or equal
to their baseline stage at the final follow-up. Rounding up,
the average progression was three stages over 3 years in
TRACK-HD (n = 73) and six stages over 6 years in
TrackOn-HD (n = 35); average regression was two stages
over 3 years in TRACK-HD (n = 17) and two stages over
6 years in TrackOn-HD (n = 6). This indicates that patients
Figure 1. (A) Regional volume biomarker positional variance diagram. Dark diagonal components indicate strong event ordering, and lighter
indicate possible event permutations with strength proportional to the off-diagonal components. (B) Re-estimation of the positional variance for
100 bootstrap samples of the data. (C) Graphic representation of the event sequence showing the corresponding subcortical regions transitioning
from an initially healthy (grey) state to an unhealthy (red) state. To aid in visualization, the newly added region at each stage is colored in orange.
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progress at approximately one stage per year, and those who
regress in stage do so by a maximum of two stages, which is
within the uncertainty in the staging mechanism.
Prediction of conversion
The EBM can also be used to predict conversion from
pre-HD to HD status. We define true converters as
patients with a premanifest diagnosis at baseline and an
HD diagnosis at year 3 (no conversions were observed at
years 1 or 2), and predicted converters as patients with a
stage greater than a threshold EBM stage. The balanced
accuracy, which is the average of sensitivity and speci-
ficity, is then maximized over all stage thresholds. This
gives a maximum balanced accuracy of 65% (75% sensi-
tivity; 55% specificity) for predicting converters with a
baseline stage greater than 7. While this might not appear
particularly high, it is worth noting that only cross-sec-
tional imaging data were used to power this prediction.
By way of comparison, support vector machines (SVM)
with linear and nonlinear kernels were trained and tested
on the same pre-HD data. Due to the small number of
converters in the sample the SVM could not improve
beyond the baseline model of just predicting the same
class at follow-up as at baseline. This highlights the ability
of the EBM to draw useful predictive information using
only cross-sectional data. Furthermore, the predictive
power is likely to be increased by including longitudinal
information in the EBM, such as the rate of atrophy.10
Correlation with phenotypic markers
To further validate the EBM, the predicted stages for pre-
HD and HD subjects were plotted as a function of three
widely used clinical markers: the total motor score
(TMS), symbol digit modalities test (SDMT), and Stroop
test. (Fig. 4A) shows a scatter plot of TMS versus stage,
(Fig. 4B) the equivalent for SDMT, (Fig. 4C) the equiva-
lent for Stroop, and (Fig. 4D) the equivalent for CAP, for
each cohort separately. Ordinary least squares linear
regression was performed on the combined cohort in each
case, which showed significant gradients (P < 0.001) in
the expected directions: TMS (b = 0.98) and CAP
(b = 0.014) increase with increasing EBM stage, SDMT
(b = 1.0) and Stroop (b = 1.4) decrease with increas-
ing EBM stage. This demonstrates the potential clinical
relevance of EBM stages despite being estimated purely
from volumetric MRI data.
Figure 2. Distribution of subject stages: healthy controls (HC), premanifest A (pre-HD A), premanifest B (pre-HD B), and manifest (HD). The
proportion is with respect to the total of each group: HC, pre-HD A + pre-HD B, and HD.
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In addition to a means of validation, the linear mod-
els in (Fig. 4A–D) allow the EBM staging to be related
to potential thresholds for motor and cognitive onset.
Example thresholds are chosen to reflect values that
separate pre-HD and HD subjects according to the lon-
gitudinal data published by2: Figure 2. For thresholds of
TMS > 15, SDMT < 40, and Stroop < 100, the EBM
predicts motor and cognitive onset for subjects with
stage >13. This suggests that by the time of onset, the
archetypal subject already has abnormal putamen, cau-
date, pallidum, insula white matter, CSF, amygdala,
optic chiasm, and (with higher uncertainty) third ven-
tricle volumes. According to this model, the posterior
insula and basal forebrain transition to an abnormal
state after motor onset. It is interesting to note that
TMS demonstrates a threshold effect and is only sensi-
tive to changes in HD subjects, not pre-HD, that is,
the pre-HD data are approximately flat, while SDMT,
Stroop, and CAP track changes across both cohorts.
Mosaic plots representing these data are shown in
(Fig. 4E–H) for each phenotype, and show a clear split
in the population above or below each threshold. This
further substantiates the EBM as a potential method to
stratify subjects.
Discussion
We have presented a uniquely fine-grained model of tem-
poral progression of volume loss in premanifest and man-
ifest HD that is robust under cross-validation. The model
provides a novel method for prediction of conversion
using imaging data alone, and we have demonstrated that
the staging can stratify premanifest subjects according to
their predicted time to onset. We evidenced the utility of
the model via longitudinal validation, and showed that
patients consistently move to later stages with time.
Finally, we showed that the model staging is significantly
correlated with independent phenotypic markers, further
supporting the model as a potential tool to support fine-
grained stratification in HD. In the following sections we
discuss how the results compare to findings in the litera-
ture, where available.
Ordering of biomarkers
Our model places the putamen, caudate, and pallidum
before insula white matter (Fig. 1A), and overall predicts a
central-to-peripheral pattern of the subcortical spread (see
(Fig. 1C) for a visual representation). This is in agreement
Figure 3. Predicted stage at baseline versus predicted stage at 1 year (A), 2 years (B), and 3 years (C) for the manifest cohort in TRACK-HD.
Predicted stages are shown as red circles (area scaled by the number of entries at each point). The uncertainty in the event ordering – equal to
that of the bootstrapped EBM positional variance – is shown as a two-dimensional heatmap.
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Figure 4. (A) Total motor score (TMS) versus event-based model (EBM) stage plus linear model fit to both pre-HD and HD subjects; (B) Symbol
Digit Modalities Test (SDMT) versus EBM stage plus linear model fit to both pre-HD and HD subjects; (C) Stroop word reading test versus EBM
stage plus linear model fit to both pre-HD and HD subjects; (D) scaled CAP score versus EBM stage plus linear model fit to both pre-HD and HD
subjects; (E) TMS versus EBM stage brackets; (F) SDMT versus EBM stage brackets; (G) Stroop versus EBM stage brackets; (H) scaled CAP score
versus EBM stage brackets. All plots show data from the premanifest (pre-HD) and manifest (HD) groups. The mosaic plots (E–H) show the lower
y-axis bracket in solid color and the higher y-axis bracket in thatch, and the number of subjects in each bracket is proportional to its area.
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with recent work by27 who used change point linear regres-
sion based on a priori disease staging to estimate the initial
time of atrophy of structural MRI in the PREDICT-HD
dataset, and observed a central-to-peripheral pattern of
atrophy from the basal ganglia to deep white matter. The
model we present here is drawn from a broader spectrum
of stages in the patient cohort than in,27 facilitating a more
complete picture of the whole disease time course, and
avoids the confounds of a priori staging.
Our findings agree well with previous studies, where
available. The early involvement of the striatum is well
reported.28–30 Early changes in the basal ganglia nuclei –
here represented by the putamen, caudate, and pallidum
– are in agreement with previous observations in both
premanifest and manifest HD subjects using the TRACK-
HD dataset,24 and with other studies based on the puta-
men and caudate.29,30 Their ordering, however, has not
previously been observed: the EBM places the putamen
strongly ahead of the caudate and pallidum, even under
bootstrapping. Abnormalities in the insula white matter
and nonventricular CSF are identified by the EBM as
potential mid-stage biomarkers, the former of which is
also reported in the PREDICT-HD dataset,27 and agrees
with observations of white matter abnormality in preman-
ifest and manifest subjects.31–34
To our knowledge, no data exist on the relative position-
ing of the remaining brain volume biomarkers. CSF has
recently been associated with seeding aggregation of
mutant Huntingtin,35 and various components have been
posited for use as clinical biomarkers.36 The EBM then pre-
dicts changes in the amygdala, optic chiasm, and third ven-
tricle. The amygdala is topologically connected to the
caudate, but the literature concerning its involvement is
sparse; where it exists, it focuses on functional tests.37 The
optic chiasm is not expected to be pathologically involved
in the disease progression, but may undergo changes in vol-
ume due to the atrophy of surrounding tissues. Measure-
ments of the volume of the third ventricle by transcranial
sonography have shown that it is significantly larger in HD
patients than HCs.38 Finally, the EBM predicts the posterior
insula and basal forebrain as late-stage biomarkers. The
posterior insula has been shown to be functionally con-
nected to the striatum and motor cortex, both of which
were identified as displaying measurable atrophy in early
manifest HD.39 Involvement of the basal forebrain in HD is
not well reported in the literature, although its neuronal
connectivity to the cerebral cortex and amygdala has been
studied in relation to the cholinergic system.40
Ordering uncertainty
The uncertainty in the event ordering, given by the posi-
tional variance (Fig. 1A), is most effectively examined
using the bootstrapped positional variance diagram shown
in (Fig. 1B). These results demonstrate that even with an
overestimation of the uncertainty, the event ordering is
largely preserved. This is particularly noteworthy given
that the model is sensitive to a number of factors present
in the data, namely, disease heterogeneity, sampling den-
sity, and statistical outliers.10
The uncertainty of the relative positions of the caudate
and pallidum is high and their positions can effectively be
permuted. There are two possible explanations for this:
(1) that the events occur simultaneously or interchange-
ably across subjects; and (2) that our cohort does not
include subjects at stages that specify the ordering of these
regions. With respect to the pallidum, measurement error
may also be an issue, due to its small size.
Staging system
The EBM provides an intrinsic staging mechanism and
hence the means to correlate the model with clinical met-
rics. The uncertainty the assigned stage depends on (1)
the accuracy of a given subject’s biomarker measurement,
and (2) the degree of overlap between the healthy and
manifest distributions. Here, we have partially addressed
these factors by statistical testing: the former by removing
outliers using, for example, the 5-sigma cut noted earlier;
and the latter by requiring that the t-tests on the HC and
HD distributions have a large effect size. We are only
using imaging data here and hence expect high hetero-
geneity leading to outliers; as discussed earlier this is
observed in a small number of subjects. Despite this we
get strongly predictive staging performance from the
EBM: it successfully divides the pre-HD group into CAG-
and age-dependent subgroups defined by the TRACK-HD
study, can perform predictions of conversion using only
cross-sectional imaging data, and has good longitudinal
consistency over 6 years. There is still a degree of uncer-
tainty associated with each subject’s stage, however; this is
reflected in the longitudinal validation, which shows a
small number of subjects regressing from their baseline
stage.
The EBM presented here uses only image-based data,
thus allowing a noncircular relationship between imaging
and phenotypic markers to be established. The results
shown in (Fig. 4) suggest an intersection of quantitative
image-based stratification and traditional clinical-based
metrics. While the thresholds used here were chosen to
split pre-HD and HD subjects into separate groups, any
number of subgroups can be defined according to the
desired level of stratification. Given the variability in the
pre-HD subject stages (Fig. 2), this type of correlation
can provide insight into potential heterogeneity in clinical
trial groups.
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Limitations and future work
As noted in10, the EBM makes model assumptions that
must be considered when interpreting these results. The
strong assumption that the disease progression is homo-
geneous across the population is common in disease
progression modelling.6 While this assumption may not
be as much of a simplification in HD (which is caused
by a single genetic mutation) as it is in Alzheimer’s dis-
ease (which typically exhibits much greater heterogene-
ity), it is reasonable to assume that the complex cascade
of both damaging and compensatory events associated
with HD causes different pathologies. Despite the
assumption of a single pattern, which is likely to be
overly simplistic, the EBM demonstrates useful staging
capability, suggesting that at least some aspects of the
progression pattern are broadly shared by most patients.
Newer techniques such as subtype and stage inference42
potentially reveal distinct patterns and may provide even
greater predictive ability in the future. In addition, as
discussed by,42 the EBM assumes independence of
biomarkers, which can affect the estimation of biomarker
event distributions. Here, we have a well-defined HC
population and strongly separated means between the
HD and HC populations, allowing for good estimation
of the biomarker event distributions, so this effect should
be negligible.
The EBM has no time dependence and hence no expli-
cit time scale; it can therefore predict where a given sub-
ject is in the disease sequence, but not how long it has
taken to reach that stage. The advantage of this is that
the EBM requires only cross-sectional data, which
enhances its clinical utility. Here, we gave the EBM an
implicit time scale in a qualitative manner by correlating
the predicted stages with phenotypic markers; the time
course of a given subject’s total motor score, for example,
can be measured and related back to the staging. This is
only an approximation, and there are associated errors
with both the stage and phenotype.
To lend the disease progression an explicit time scale a
different model could be applied that utilizes longitudinal
data (see 44 for a more comprehensive review). Trajec-
tory-based models that are informed by patient data have
been proposed that employ linear mixed models44 or
quantile regression,45 with the latter allowing for non-
monotonic trajectories. However, these models require an
a priori definition of disease stage; in the cited examples,
this is expected age to onset and time to diagnosis,
respectively, both of which need to be estimated. In prac-
tice, these estimates are crude, for example, from parental
age of onset, which can lead to inaccuracy of the model.
Trajectory modeling without the need for a predefined
disease stage can be achieved using differential
equation models46,47 and self-modeling regression tech-
niques48 or Gaussian Processes.43 Such models provide
complete temporal pictures of disease progression at the
expense of requiring data from at least two time points to
parameterize.
Future work on validating the model across multiple
datasets will be valuable for translation to clinical prac-
tice. We plan to use data from the PREDICT-HD study
to test the model, as it represents a different cohort
and will allow us to probe the effects of population
variance. Furthermore, we will specify models to each
study separately and compare the predicted progression
patterns.
Conclusions
We have presented a data-driven model of brain volume
biomarker changes in Huntington’s disease that shows
good longitudinal consistency and potential clinical appli-
cability. The model proposes a characteristic sequence of
events with a strong ordering that provides insight into
Huntington’s disease progression and a potential tool for
patient stratification.
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